A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck

Seiwert, TY; Fayette, J; Cupissol, D; Del Campo, JM; Clement, Paul; Hitt, R; Degardin, M; Zhang, W; Blackman, A; Ehrnrooth, E; Cohen, EEW

doi:10.1093/annonc/mdu216

A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck

Author:

Seiwert, TY

Fayette, J ; Cupissol, D ; Del Campo, JM ; Clement, Paul ; Hitt, R ; Degardin, M ; Zhang, W ; Blackman, A ; Ehrnrooth, E ; Cohen, EEW

Keywords:

Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Carcinoma, Squamous Cell, Cetuximab, Female, Head and Neck Neoplasms, Humans, Male, Middle Aged, Quinazolines, Receptor, Epidermal Growth Factor, Receptor, ErbB-2, Treatment Outcome, Young Adult, Science & Technology, Life Sciences & Biomedicine, Oncology, afatinib, cetuximab, recurrent HNSCC, metastatic HNSCC, EGFR inhibitor therapy, QUALITY-OF-LIFE, EUROPEAN-ORGANIZATION, LUNG ADENOCARCINOMA, PLUS CETUXIMAB, CANCER, INHIBITOR, ERLOTINIB, TOXICITY, TRIALS, GROWTH, Afatinib, ErbB Receptors, Squamous Cell Carcinoma of Head and Neck, Receptor, erbB-2, 1112 Oncology and Carcinogenesis, Oncology & Carcinogenesis, 3202 Clinical sciences, 3211 Oncology and carcinogenesis

Abstract:

Afatinib is an oral, irreversible ErbB family blocker that has shown activity in epidermal growth factor receptor (EGFR)-mutated lung cancer. We hypothesized that the agent would have greater antitumor activity compared with cetuximab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients, whose disease has progressed after platinum-containing therapy.